OTTAWA, Sept. 27, 2017 /CNW/ - A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc. The Panel has found that the price of Soliris (eculizumab) 10 mg/mL was and is excessive under sections 83 and 85 of the Patent Act. The Panel has ordered Alexion to pay to Her Majesty in right of Canada an amount calculated in accordance with Schedule A to this decision. The Hearing Panel has also ordered Alexion to lower the list price of Soliris in Canada as of September 20, 2017 to no higher than the lowest price in the seven comparator countries set out in the Patented Medicines Regulations.
Quick Facts
Related Products
Associated Links
SOURCE Patented Medicine Prices Review Board
These press releases may also interest you
|